Hong Kong Med J 2025;31(Suppl 1):S19-22
Add-on astragalus therapy for diabetic kidney disease: an open-label randomised controlled trial with responder regression analysis (abridged secondary publication)
KW Chan1, ASK Kwong2, PN Tsui3, GCW Chan4, WF Choi5, WH Yiu1, SCY Cheung6, Y Zhang6 MMY Wong3, BJ Cowling7, Z Zhang6, KCB Tan8, Y Feng6, LX Lao5,9, KN Lai1, SCW Tang1
1 Division of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
2 Department of Family Medicine and Primary Healthcare, Hospital Authority Hong Kong West Cluster, Hong Kong SAR, China
3 Department of Family Medicine and Primary Healthcare, Hospital Authority Hong Kong East Cluster, Hong Kong SAR, China
4 Division of Nephrology, Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China
5 School of Chinese Medicine, The University of Hong Kong, Hong Kong SAR, China
6 Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, China
7 School of Public Health, The University of Hong Kong, Hong Kong SAR, China
8 Division of Endocrinology, Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
9 Virginia University of Integrative Medicine, Virginia, USA
 
 
  1. Add-on astragalus treatment for 48 weeks significantly improves kidney function in patients with stage 2 to 3 chronic diabetic kidney disease and macroalbuminuria.
  2. The improvement occurs independently of blood pressure, blood glucose, and albuminuria control.